Please assess the completion status of the following clinical trial:

Trial Title: Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected children~* Resident in Cape Town~* Informed consent obtainable~* weight \> 2.5kg~* Access to transport~* HAART use for not less than 2 months but not more than 12 months with no significant demonstrated toxicity and good adherence~Exclusion Criteria:~* Chronic diarrhoea~* Current use of INH prophylaxis~* Prior hypersensitivity to INH prior history of allergy to sulphur drugs~* Prior history of allergy to sulphur drugs~* Severe anaemia (haemoglobin less than 7 gm/dl)~* Neutropenia (absoloute neutrophil count less than 400 cells)~* Thrombocytopenia (platelet count \< 50 000/uL)~* Non-reversible renal failure~* Clinical hepatitis~* Exposure to household TB contact, requiring INH prophylaxis

- Gender: ALL
- Minimum Age: 8 Weeks
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Isoniazid preventive therapy (Type: EXPERIMENTAL): HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
- Placebo (Type: PLACEBO_COMPARATOR): HIV infected children living in a high TB prevalence area receive placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).